Bristol Myers Squibb and Johnson & Johnson Launch Educational Program for Thromboembolic R&D
Bristol Myers Squibb and Johnson & Johnson have launched the “Change the Target. Change What’s Possible” educational initiative focused on Factor XIa inhibition for thromboembolic disease. The program highlights FXIa’s potential to prevent harmful clots while preserving normal hemostasis, addressing the bleeding risk that limits current anticoagulants. The collaboration leverages both companies’ scientific and commercial strengths to educate clinicians and accelerate research. It targets unmet needs in cardiovascular care, where roughly one million U.S. deaths and significant treatment gaps persist.
MPATH® Health Earns DiMe Seal for Quality and Trust in Digital Health
mPATH® Health announced that its cancer‑screening platform has earned the Digital Medicine Society’s DiMe Seal, a mark of quality and trust for digital health software. The seal evaluates products on evidence, usability, privacy, security and equity, confirming that mPATH meets...
Nine Biotech Companies that Could Revolutionize Obesity Treatments
A slate of nine biotech firms is accelerating the race to treat obesity, each advancing GLP‑1, GIP or novel oral formulations toward market approval. Early‑stage data from companies such as Zealand Pharma, Viking Therapeutics and Structure Therapeutics report weight‑loss results...
Infrared-Activated Hydrogel Uses Lysozyme 'Nets' To Combat Resistant Bacteria
Researchers at ETH Zurich and Shanghai University have created an infrared‑activated hydrogel that mimics neutrophil extracellular traps. The gel, built from egg‑white lysozyme fibers, releases active lysozyme and magnesium ions when exposed to near‑infrared light, killing resistant bacteria and calming...
The Role of Standards in Sustainability
Sustainability has moved from a niche environmental concern to a core business driver for pharmaceutical manufacturers. The United States Pharmacopeia (USP), whose standards are adopted by more than 22,000 facilities in 140 countries, is leveraging its reach to embed ecological...
Pfizer Takes $4.4B Charge Related to Cancer Drug in Fourth-Quarter Earnings
Pfizer reported fourth‑quarter earnings that included a $4.4 billion non‑cash charge tied to a recent high‑profile cancer‑drug acquisition. The write‑down lowered net income but the company highlighted a positive Phase III readout for a separate oncology candidate. Management said the data could...
FDA Knocks Back AstraZeneca's Self-Injected Lupus Drug
AstraZeneca's subcutaneous formulation of its lupus biologic Saphnelo was rejected by the FDA, receiving a complete response letter despite recent European approval. The IV version continues to grow, posting $483 million in sales for the first nine months of 2025, and...
Pfizer’s Metsera-Originated Monthly GLP-1 Cuts Weight by 10.5% at Six Months
Pfizer announced that its monthly GLP‑1 obesity drug, originated from the Metsera acquisition, achieved an average 10.5% weight reduction after six months in a late‑stage study. The therapy’s once‑monthly dosing is designed to improve patient adherence compared with weekly injectables....
AstraZeneca Gets CRL for Prefilled Pen Version of Lupus Drug Saphnelo
The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for AstraZeneca's subcutaneous prefilled‑pen version of Saphnelo, its anifrolumab therapy for systemic lupus erythematosus (SLE). The CRL indicates the agency found deficiencies—primarily around additional safety and manufacturing data—requiring...
Genetic Variability of Voltage-Gated Sodium Channel NaV1.2
A new study by Oliveira‑Madureira, Leal and Azevedo maps the structural impact of genetic variability in the neuronal sodium channel NaV1.2. Using high‑resolution cryo‑EM and X‑ray crystallography, the authors detail how specific mutations and post‑translational modifications reshape the channel’s conformation...
UK Will Cover Transport Costs for Children with Cancer
The UK government will allocate a £10 million fund to cover transport costs for children and young people up to age 24 diagnosed with cancer, with the scheme rolling out by 2027. The support is universal, irrespective of household income, and...
Phenotypic Age Predicts Mortality Risk in Parkinson's Disease Patients
The post discusses a new study using the Phenotypic Age (PhenoAge) clock to predict mortality risk in Parkinson's disease (PD) patients, finding that higher PhenoAge and its acceleration are strong independent predictors of death alongside factors like age, male sex,...
A Deeper Investigation of Recent Trends in Life Expectancy
A new study of 450 sub‑national regions in 13 Western European countries reveals stark regional disparities in life expectancy trends. Researchers identify two distinct phases: a "golden era" from 1992‑2005 with robust gains of roughly 2.5 months per year for...
Injectable Thermogel‐Loaded Bi2S3 Nanorods for Synergistic Photothermal Bacterial Elimination and Anti‑Inflammation to Remodel Periodontitis Microenvironment
Researchers have created an injectable, thermosensitive hydrogel (Bi2S3@Gel) loaded with bismuth sulfide nanorods that activates under near‑infrared light. The material delivers mild photothermal heating, amplifies reactive oxygen species, and depletes glutathione, achieving potent antibacterial action. At the same time, the...
Ligand‐Driven Optimization of Iron Oxide Nanoprobes for In Vivo MRI Enhancement at Ultra‐High Field
Researchers developed a ligand‑driven method to fine‑tune T2 relaxivity of 12 nm iron‑oxide nanoparticles for ultra‑high‑field MRI. By exchanging five surface coatings—PAA, PMA, PMAO, citric acid and silica—they achieved up to a 333 mm⁻¹ s⁻¹ increase in r₂, with citric‑acid‑coated particles reaching record...
Machine Learning Predicts Fontan Failure and Liver Disease
A recent study led by Prasad et al. applied machine learning to multi‑parametric abdominal MRI radiomics, creating models that predict Fontan failure and assess Fontan‑associated liver disease severity. The algorithms identified specific imaging features that signal advanced liver disease well...
Oral Treprostinil: Safety and Efficacy in PAH Patients
A multicenter Phase III trial evaluated oral treprostinil in patients with pulmonary arterial hypertension (PAH), demonstrating statistically significant improvements in exercise capacity and hemodynamics. Over 12 months, the drug increased six‑minute walk distance by an average of 30 meters and lowered pulmonary vascular...
ProofPilot CEO Chris Venezia Joins RealTime eClinical Solutions BOD
ProofPilot CEO Chris Venezia has been appointed to the Board of Directors of RealTime eClinical Solutions. The appointment aligns with RealTime’s strategy to tighten site‑sponsor connections and speed trial execution under new CEO Jeff Kozloff. Venezia brings more than two...
Speckle Echo Reveals Hidden Heart Issues in Epileptic Kids
A recent study using speckle-tracking echocardiography uncovered previously undetected cardiac abnormalities in children with epilepsy. The imaging technique identified subclinical myocardial dysfunction in roughly 30% of the cohort, despite normal conventional echo results. Researchers attribute these findings to potential shared...
Assessing Hip Fracture Risk: Costa Rica’s Unique Insights
A new epidemiological study from Costa Rica has mapped hip‑fracture risk among its aging population, revealing distinct regional and lifestyle determinants. Researchers analyzed over 12,000 medical records, linking low bone mineral density, calcium‑poor diets, and limited access to preventive care...
Magneto-Mechanical Forces Reprogram Macrophages for Tumor Immunity
Researchers have demonstrated that dynamic magneto‑mechanical forces applied within lysosomes can durably repolarize tumor‑associated macrophages from an M2 to an M1 phenotype. By loading macrophages with engineered magnetic nanoparticles and exposing them to alternating magnetic fields, the team triggered lysosomal...
BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline
BioNTech is outpacing Moderna by expanding beyond mRNA into a multi‑modality oncology pipeline, highlighted by its $3.5 billion pumitamig partnership and several Phase III candidates. Moderna, still anchored to mRNA, has seen COVID‑19 vaccine revenues plunge from $18.4 billion in 2022 to $3.1 billion...
Corn Cob Biochar Filters Pull Ammonia and Micro and Nanoplastics From Water
Researchers at the University of Delaware have converted discarded corn cobs into high‑performance biochar filters that simultaneously adsorb dissolved ammonia and micro‑/nanoplastic particles. In lab tests, the optimized 700 °C corn‑cob biochar (CCB700) removed about 64% of ammonia at 10 ppm and...
As Amgen and Lilly Recommit, Puerto Rico Seeks To Regain Manufacturing Momentum
Amgen and Eli Lilly have pledged more than $1.8 billion to expand their Puerto Rico facilities, with Amgen allocating $650 million to its Juncos biologics plant and Lilly committing over $1.2 billion to modernize its Carolina site for oral GLP‑1 production. These investments arrive as...
Daratumumab Shows Promise in Lupus Phase 2 Trial
A single‑arm phase 2 trial evaluated daratumumab, a CD38‑targeting antibody approved for multiple myeloma, in patients with refractory systemic lupus erythematosus. The study reported significant reductions in SLEDAI and BILAG disease activity scores, accompanied by declines in circulating plasma cells and...
Paclitaxel Expands TREM2+ Macrophages, Reducing Efficacy
A recent preclinical study reveals that paclitaxel treatment expands TREM2‑positive macrophages within the tumor microenvironment, dampening anti‑tumor immune responses. The increase in these immunosuppressive cells correlates with a measurable reduction in paclitaxel’s cytotoxic efficacy across several cancer models. Researchers demonstrated...
Biotech’s 2026 Catalysts. Plus: China’s New Orphan Rules — a BioCentury Podcast
The BioCentury podcast outlines the most consequential biotech catalysts slated for 2026, highlighting over thirty late‑stage trials that could reshape therapeutic landscapes. It also examines China’s newly enacted orphan‑drug regulations, which lower approval thresholds and introduce tax incentives for rare‑disease...
EMA’s CHMP Backs Six New Products in January
In January 2026 the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions on six new medicines, marking a busy month for European regulators. Among the approvals, Sanofi’s Rezurock (benedosudil) secured a conditional marketing authorization...
Immunotherapy Blocking Microglial FcγR Prevents Neuron Loss in Parkinson’s Disease
Researchers identified that microglia in Parkinson’s disease express elevated low‑affinity Fcγ receptors (CD16/CD32), which mistakenly target healthy dopaminergic neurons for phagocytosis. Using post‑mortem tissue, mouse models, and cell cultures, they demonstrated that blocking these receptors with neutralizing antibodies—or inhibiting downstream...
At Least Nine PDUFAs on FDA February Docket
The FDA’s February docket lists at least nine PDUFA submissions, including five prospective new products and four indication extensions. Four of the entries are gene‑therapy candidates targeting rare lysosomal disorders, highlighting the sector’s reliance on AAV platforms. RegenxBio’s RGX‑121 for...
Spatiotemporal Mapping of Brain Organisation Following the Administration of 2C-B and Psilocybin
A double‑blind, crossover fMRI study in 22 healthy volunteers compared the acute neural effects of 20 mg 2C‑B, 15 mg psilocybin, and placebo. Both psychedelics reduced within‑network static functional connectivity while broadly increasing between‑network and global connectivity, and they elevated multiple measures...
A Systematic Review and Meta-Analysis of the Auditory Steady-State Response in Schizophrenia, Bipolar Disorder, and Autism Spectrum Disorder
A comprehensive systematic review and meta‑analysis examined auditory steady‑state responses (ASSR), particularly the 40 Hz gamma band, across schizophrenia, bipolar disorder, and autism spectrum disorder. The analysis pooled data from over 60 studies, revealing robust reductions in ASSR amplitude and phase‑locking...
Bariatric Surgery Transformed by GLP-1 Receptor Agonists
A recent narrative review by Muhundan and Dash highlights the emerging practice of pairing GLP‑1 receptor agonists with bariatric surgery to improve weight‑loss durability. The authors argue that GLP‑1RAs can augment hormonal satiety pathways, reducing postoperative weight regain and enhancing...
Automating Microfluidic Chip Design: Hybrid Approach Combines Machine Learning with Fluid Mechanics
Researchers at Koç University unveiled μFluidicGenius (μFG), an open‑access tool that automates microfluidic chip design by blending machine‑learning models with classic fluid‑mechanics calculations. Users input reservoir locations, channel connections, and target flow rates, while the system generates maze‑like channel geometries...
Identifying Mechanisms that Support Nanoparticle Therapy for Autoimmune Diseases
Northwestern Medicine researchers identified how a biodegradable nanoparticle therapy induces antigen‑specific tolerance in autoimmune disease models. The study shows myeloid cells ingest the particles, undergo apoptosis, and release oxidized DNA that activates the STING pathway, leading to type‑I interferon production....
NTLA Plunges 25% Despite Hold‑lift Skepticism
$NTLA down >25% since the cultists tried to dunk on me after the hold lift. Down >15% since the high $15s when I made the post below *before* the hold lift, saying that a potential hold lift wouldn't actually...
Researchers Identify Key Gene for Enhancing Oil Yield and Quality in Jatropha
Researchers at the Chinese Academy of Sciences identified the JcSPL9 gene as a master regulator of seed yield and oil content in Jatropha curcas. Overexpressing a miR156‑resistant version (rJcSPL9) increased seed numbers by roughly 81% and oil concentration by 12.6%...
Fibrosis in Uterine Leiomyomas: Impact of Race and Genetics
A new multi‑institutional study links higher fibrosis levels in uterine leiomyomas to both racial background and specific genetic variants. Researchers analyzed tumor samples from over 1,200 women, finding that Black patients exhibited 30% more collagen deposition than White patients. Genome‑wide...
Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration
Genentech, part of Roche, signed a global licensing deal with Chinese biotech SanegeneBio to develop an undisclosed RNA interference program. The agreement includes a $200 million upfront payment and up to $1.5 billion in milestone‑linked payments, plus royalties. SanegeneBio retains early‑stage development...
Carbon Health Files for Bankruptcy, Seeking to Sell or Restructure
Carbon Health, a fast‑growing urgent and primary‑care startup, announced it has filed for Chapter 11 bankruptcy protection. The filing aims to either restructure the business or find a buyer. The company, which previously raised more than $800 million and operated hundreds...
How Aircraft Wing Physics Could Accelerate the Next Generation of RNA Medicines
Researchers at University College Dublin have created an aerofoil‑shaped microfluidic platform that delivers consistent lipid nanoparticle (LNP) formulations from milliliter‑scale screening to liter‑scale production. The MiNANO‑form cartridge can run eight parallel, contamination‑free mixes using as little as 0.1 mL of reagents,...
Two-Step Approach Creates More Sustainable Protein Nanostructures for Advanced Sensing and Therapeutics
Researchers at Rice University introduced a two‑step, dual‑inducer genetic system that decouples the expression of gas vesicle assembly factors from the shell protein in Escherichia coli. By giving assembly factors a two‑ to three‑hour head start, the method reduces cellular...
First 10 Medicare-Negotiated Drug Prices Have Taken Effect: Are Seniors Really Saving Money?
The first ten drugs subject to Medicare price negotiations under the Inflation Reduction Act took effect in early 2024, with the government projecting billions of dollars in annual savings. Early data indicate that the negotiated caps have lowered list prices...
Bioinspired Synthetic Biology Powers Energy-Efficient Electronics
Researchers at the University of Cambridge have unveiled a bio‑inspired synthetic‑biology platform that creates protein‑based semiconductors, cutting power draw by up to 70% versus conventional silicon. The self‑assembling peptide circuits are flexible, biodegradable, and have been integrated into prototype low‑power...
Mutation Map Indicates How Alterations in Key Cancer Gene Influence Tumor Growth
An international team led by the University of Edinburgh created a comprehensive functional map of 342 possible missense mutations in the CTNNB1 hotspot, assigning activity scores to over 80% of cancer‑observed variants. Using mouse stem cells and genome‑editing, they measured...
Sinorda and WuXi Partner on Bispecific Antibody Development and Manufacturing
Sinorda Biomedicine has teamed with WuXi Biologics to develop and manufacture SND006, a bispecific antibody aimed at treating inflammatory bowel disease and other autoimmune conditions. The partnership leverages WuXi’s extensive biologics expertise to accelerate preclinical pharmacology, clinical‑supply manufacturing, and IND...
Lab-Grown Algae Remove Microplastics From Water
University of Missouri engineer Susie Dai has genetically engineered algae that secrete limonene, rendering them water‑repellent and capable of aggregating microplastics into sinkable clumps. The algae simultaneously consume excess nutrients, allowing the combined biomass‑plastic aggregates to be harvested from wastewater....
Synthetic Compound Shows Promise in Treating Malaria and Blocking Its Transmission
Researchers have unveiled a novel synthetic compound that dramatically reduces malaria parasite levels in animal models and simultaneously blocks transmission to mosquitoes. In pre‑clinical trials, the molecule achieved over 90% clearance of blood‑stage parasites and a 95% reduction in gametocyte...
Exercise as a Way to Enhance DNA Repair to Slow Aging
An open‑access review links regular exercise to enhanced DNA‑repair pathways that may decelerate muscle aging. It outlines two emerging mechanisms: somatic mosaicism from stem‑cell mutations and epigenetic drift driven by repeated double‑strand break repair. The paper highlights how chronic training...
New CagriSema Data Show Improvement over Semaglutide
Novo Nordisk disclosed Phase III data showing its next‑generation metabolic therapy CagriSema outperformed the GLP‑1 blockbuster semaglutide in type 2 diabetes. The trial reported larger reductions in HbA1c and greater body‑weight loss while maintaining a comparable safety profile. CagriSema’s superiority was observed...